Details for Patent: 8,859,551
✉ Email this page to a colleague
Title: | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
Abstract: | In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: ##STR00001## wherein each of R.sub.1, R.sub.2, and R.sub.3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R.sub.4 and R.sub.5 is independently hydrogen, alkyl, or alkoxy; and each of R.sub.6 and R.sub.7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A.sub.1, A.sub.3, and A.sub.4 is independently hydrogen or alkyl; and A.sub.2 is independently hydrogen or hydroxy; and wherein each of B.sub.1, B.sub.2, and B.sub.3 is independently hydrogen, hydroxy, or alkoxy; and each of B.sub.4 and B.sub.5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith. |
Inventor(s): | DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ) |
Assignee: | Galderma Laboratories Inc. (Fort Worth, TX) |
Filing Date: | Feb 25, 2013 |
Application Number: | 13/775,784 |
Claims: | 1. A method of reducing the severity of one or more symptoms of an inflammatory dermatologic disorder related to the skin in a subject, the method comprising topically administering to the skin of a subject in need of such reduction an effective amount of brimonidine or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the method comprises topically administering brimonidine tartrate. 3. A method of reducing the severity of an inflammatory dermatologic disorder related to the skin in a subject, the method comprising topically administering to the skin of a subject in need of such reduction an effective amount of brimonidine or a pharmaceutically acceptable salt thereof. 4. The method of claim 3, wherein the method comprises topically administering brimonidine tartrate. |